Active Biotech (ACTI) investor relations material

Strategic focus and pipeline

• Refocused on specialist disease areas with large unmet medical needs, particularly in oncology and inflammation.

• Key assets include tasquinimod (hematological malignancies) and laquinimod (inflammatory eye disorders).

• Tasquinimod is in Phase I/II studies for myelofibrosis and multiple myeloma, with Orphan Drug Designation in the US.

• Laquinimod has completed Phase I for eye disorders and is advancing with a partner.

• Naptumomab is licensed to NeoTX for global development in solid tumors.

Tasquinimod clinical and market insights

• Tasquinimod targets rare blood cancers, with ongoing clinical trials in myelofibrosis and multiple myeloma.

• Demonstrates disease-modifying potential and synergistic effects with JAK and BET inhibitors.

• Clinical benefit rate of 47% in heavily pretreated multiple myeloma patients when combined with IRd.

• Orphan Drug Designation provides regulatory and market exclusivity advantages.

• Market opportunities in myelofibrosis and multiple myeloma estimated at $21bn and $2.3bn, respectively.

Laquinimod development and potential

• First-in-class hydrogel eye drop formulation for non-infectious uveitis and other eye disorders.

• Demonstrated safety, tolerability, and effective ocular distribution in Phase I trials.

• Preclinical and clinical data support both topical and oral efficacy in reducing inflammation.

• Patent protection extends through 2042, ensuring long-term exclusivity.

• Addressable market for non-anterior non-infectious uveitis estimated at 550,000 patients and $1.5bn by 2033.